SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Policy
BMS-Sponsored Diversity in Oncology Series Tackles Representation in Clinical Trials
BMS partnered with digital oncology company GRYT Health to convene a series of “courageous conversations” between patients, practitioners, caregivers, clinical trial teams and public health leaders.
April 5, 2022
 · 
7 min read
 · 
Heather McKenzie
From left: Amylyx Co-founders and Co-CEOs Justin K
Drug Development
Amylyx ALS Candidate Denied in Painfully Close AdCom Vote (Updated)
In a meeting of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee, six members voted not to approve the NDA for Amylyx’s ALS candidate, AMX0035, while four voted in favor.
March 30, 2022
 · 
4 min read
 · 
Heather McKenzie
Civica is putting in efforts to make affordable in
Business
Civica is Rallying Leaders to Make Affordable Insulin by 2024
Civica plans to make versions of three affordable insulins available at significantly reduced costs by 2024. You can explore the other aspirations here in this article.
March 28, 2022
 · 
8 min read
 · 
Heather McKenzie
From left: Amylyx Co-founders and Co-CEOs Justin K
Drug Development
UPDATED: Amylyx - and Hopeful ALS Community – Face Another Moment of Truth
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will face its first big test since Aduhelm as it weighs the merits of Amylyx’s AMX0035 for ALS on Wednesday, March 30.
March 27, 2022
 · 
8 min read
 · 
Heather McKenzie
Omega Therapeutics team, Courtesy Omega Therapeuti
Business
Modulating Gene Expression to Stop Diseases in Their Tracks: a Pioneering Journey
Omega Therapeutics is harnessing the power of epigenetics in an unprecedented way and engineering programmable epigenetic mRNA therapeutics to transform medicine in the service of patients.
March 20, 2022
 · 
6 min read
 · 
Heather McKenzie
A Novartis building under a blue sky/courtesy of C
Drug Development
Novartis’ Fortuitous Discovery Could Deliver Breakthrough in Huntington’s Disease
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
March 19, 2022
 · 
4 min read
 · 
Heather McKenzie
Nitpicker/Shutterstock
Drug Development
BMS Celebrates A New Day in Cancer Treatment with Approval of Opdualag
BMS achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of melanoma.
March 19, 2022
 · 
3 min read
 · 
Heather McKenzie
Pavel Kapysh/Shutterstock
Drug Development
New NurOwn Data Backs Up Importance of UNC13A in ALS
BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.
March 16, 2022
 · 
3 min read
 · 
Heather McKenzie
Photos courtesy of Shoreline Biosciences, Axogen a
Life Sciences Industry Emphasizes Growth, Purpose in Fight for Talent
According to a recent BioSpace report, the top three motivators for employees to look for a new job are growth opportunities, greater compensation and the desire for a new challenge.
March 15, 2022
 · 
5 min read
 · 
Heather McKenzie
Business
Sanofi Unites Under a Single Purpose at Cambridge Crossing
Cambridge Crossing will enable innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among other key modalities.
March 11, 2022
 · 
5 min read
 · 
Heather McKenzie
Courtesy of Daiichi Sankyo
Business
Daiichi Sankyo is Embarking on Mission Possible
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
March 5, 2022
 · 
5 min read
 · 
Heather McKenzie
Drug Development
Biopharma Takes a Decisive Position on the Russia-Ukraine Conflict
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
March 1, 2022
 · 
4 min read
 · 
Heather McKenzie
Acrotech President Dr. Ashish Anvekar/courtesy Act
Drug Development
A Platform for Hope in the Face of Rare and Uncommon Diseases
Acrotech is looking to launch drugs with either improved efficacy and/or safety over currently available treatments in the oncology, dermatology, neuroscience and rare disease spaces.
February 28, 2022
 · 
4 min read
 · 
Heather McKenzie
Drs. Neely Mozaffarian and Hong Sun, Janssen Immun
Drug Development
Janssen is Taking a Big Swing at Autoantibody-Driven Diseases
With nipocalimab, Janssen is hoping to take one big swing and knock the power right out of these autoantibodies.
February 27, 2022
 · 
4 min read
 · 
Heather McKenzie
Andrew McKnight, KKNA (Kyowa Kirin), Joel Martin (
Business
An Enduring Drug Discovery Partnership Built on Complimentary Qualities
The arrangement provides the opportunity for LJI faculty and postdocs to make a more immediate impact on drug development while offering a different perspective to KKNA.
February 24, 2022
 · 
6 min read
 · 
Heather McKenzie
Load More